目的 觀察腦栓通膠囊聯(lián)合注射用尤瑞克林治療急性腦梗死的臨床療效。方法 選取南陽(yáng)市第二人民醫(yī)院2015年1月-2018年12月收治的急性腦梗死患者150例，隨機(jī)分為對(duì)照組和治療組，每組各75例。對(duì)照靜脈滴注注射用尤瑞克林，0.15 PNA單位溶于50 mL或100 mL生理鹽水中，靜滴30 min，1次/d；治療組患者在對(duì)照組治療基礎(chǔ)上口服腦栓通膠囊，3粒/次，3次/d。兩組患者均治療2周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者內(nèi)皮素-1（ET-1）、N末端B型鈉尿肽原（NT-proBNP）、腫瘤壞死因子-α（TNF-α）水平及臨床癥狀改善情況。結(jié)果 治療后，對(duì)照組和治療組臨床有效率分別為81.33%和92.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者ET-1、NT-proBNP、TNF-α水平均顯著下降（P<0.05），且治療組患者ET-1、NT-proBNP、TNF-α水平顯著低于對(duì)照組（P<0.05）。治療后，兩組患者NIHSS評(píng)分顯著降低（P<0.05），且治療組患者NIHSS評(píng)分顯著低于對(duì)照組（P<0.05）。結(jié)論 腦栓通膠囊聯(lián)合注射用尤瑞克林治療急性腦梗死，能有效改善患者的臨床癥狀，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effect of Naoshuantong Capsules combined with uriklin in treatment of acute cerebral infarction. Methods Patients (150 cases) with acute cerebral infarction in Nanyang Second People's Hospital from January 2015 to January 2018 were randomly divided into control and treatment groups, and each group had 75 cases. Patients in the control group were iv administered with Urinary Kallidinogenase for injection, 0.15 PNA dissolved into normal saline 50 mL or 100 mL, and dripped for 30 min, once daily. Patients in the treatment group were po administered with Naoshuantong Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, the ET-1, NT-proBNP, and TNF-α levels and the improvement of clinical symptoms in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 81.33% and 92.00%, respectively, and there were differences between two groups (P<0.05). After treatment, the ET-1, NT-proBNP, and TNF-α levels in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the NIHSS scores in two groups were significantly decreased (P<0.05), and the scores in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Naoshuantong Capsules combined with uriklin in treatment of acute cerebral infarction can improve the symptoms, which has a certain clinical application value.

R971